C-CAR031

Phase 1Small molecule

ZZhejiang University

C-CAR031 is one of 75 small molecule programs targeting Lung Cancer. It is currently in Phase 1.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Lung CancerRecruiting

Hepatocellular CarcinomaRecruiting

Lung CancerPhase 1

Recruiting

Hepatocellular CarcinomaPhase 1

Recruiting

Competition

Competitive Landscape

265 competitors in Hepatocellular Carcinoma

#DrugCompanyPhaseTrials

Cysteine Hydrochloride

Novartis

Preclinical

1 2

Ibrance

Pfizer

Preclinical

1 3

Viread

Gilead

Preclinical

1 4

Sovaldi

Gilead

Preclinical

1 5

Hepsera

Coreg

2 7

Miraclid

TTechpool Bio-Pharma Co., Ltd.

Preclinical

1 8

Doptelet

AAkarx

Preclinical

1 9

Vermox

WWim Janssens

Preclinical

1 10

Valemetostat

Bristol-Myers Squibb

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q1 2028

Phase 1Recruiting

Lung Cancer

NCT07444281

Q2 2041

Phase 1Recruiting

Hepatocellular Carcinoma

NCT05155189

Clinical

Trials by Indication[1]

Hepatocellular Carcinoma1 trial

A Study to Evaluate Safety and Efficacy of Armored CAR-T Cell Injection C-CAR031 in Advanced Hepatocellular Carcinoma

Recruiting·ZZhejiang University·Phase 1·NCT05155189·72 enrolled

Lung Cancer1 trial

An Phase I Trial of a CAR T-cell Infusion C-CAR031 in Participants With GPC3+ Advanced/Metastatic Squamous Cell Lung Cancer

Recruiting·SShanghai AbelZeta Ltd.·Phase 1·NCT07444281·24 enrolled

Sources

References

[1]
ClinicalTrials.gov — 2 trial records for C-CAR031. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — C-CAR031 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for C-CAR031. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Zhejiang University company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 1[1]
Company: ZZhejiang University

C-CAR031

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q1 2028

Q2 2041

Trials by Indication[1]

Hepatocellular Carcinoma1 trial

Lung Cancer1 trial

References

Drug Info

Quick Facts

Related News